2024
Interventional Oncology Meets Immuno-oncology: Combination Therapies for Hepatocellular Carcinoma.
Bitar R, Salem R, Finn R, Greten T, Goldberg S, Chapiro J. Interventional Oncology Meets Immuno-oncology: Combination Therapies for Hepatocellular Carcinoma. Radiology 2024, 313: e232875. PMID: 39560477, PMCID: PMC11605110, DOI: 10.1148/radiol.232875.Peer-Reviewed Original ResearchConceptsManagement of hepatocellular carcinomaHepatocellular carcinomaLocoregional therapyClinical trialsImage-guided locoregional therapiesEnd pointsStages of hepatocellular carcinomaTumor microenvironment mechanismsCatheter-directed therapyCombination of immunotherapyProspective clinical trialImaging end pointsStandard of careAdjuvant settingNovel immunotherapiesCombination therapyTherapy resistanceInterventional radiologistsImmunotherapyDisease stageTherapyDisease evolutionNovel biomarkersCarcinomaMicroenvironment mechanismsImmunometabolism of CD8+ T cell differentiation in cancer
Shi H, Chen S, Chi H. Immunometabolism of CD8+ T cell differentiation in cancer. Trends In Cancer 2024, 10: 610-626. PMID: 38693002, PMCID: PMC11342304, DOI: 10.1016/j.trecan.2024.03.010.Peer-Reviewed Original ResearchCD8<sup>+</sup> cytotoxic T lymphocytesT cell receptorImmune signalingCD8+ T cell differentiationMediators of tumor immunityTumor antigen recognitionCytotoxic T lymphocytesT cell differentiationTumor-immune interactionsTumor immunityNovel immunotherapiesT lymphocytesIntracellular metabolic pathwaysCo-stimulationAntigen recognitionMetabolic programmingDesign novel immunotherapiesImmunotherapyCentral mediatorsMetabolic landscapePost-transcriptional mechanismsTumorBidirectional regulationSignaling eventsMetabolic processesUnderstanding and overcoming resistance to immunotherapy in genitourinary cancers
Evans S, Jani Y, Jansen C, Yildirim A, Kalemoglu E, Bilen M. Understanding and overcoming resistance to immunotherapy in genitourinary cancers. Cancer Biology & Therapy 2024, 25: 2342599. PMID: 38629578, PMCID: PMC11028033, DOI: 10.1080/15384047.2024.2342599.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsResistance to immunotherapyImmunotherapy resistanceTargeted therapyGenitourinary (GU) cancersCombined immune checkpoint inhibitorsIntroduction of novel immunotherapiesMechanisms of immunotherapy resistanceOvercome resistance to immunotherapyCancer cellsHost immune profileResponse to immunotherapyNovel targeted therapiesImmune system's rolePredictors of responseAttack cancer cellsImmune system's abilityStandard of careCheckpoint inhibitorsSequential therapyNovel immunotherapiesCombination therapyTreatment failureGU cancersTreatment landscape
2023
New Therapies in Melanoma: Current Trends, Evolving Paradigms, and Future Perspectives.
Shafi S, Challa B, Parwani A, Aung T. New Therapies in Melanoma: Current Trends, Evolving Paradigms, and Future Perspectives. Cutis 2023, 112: e32-e39. PMID: 38091429, DOI: 10.12788/cutis.0911.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsLymphocyte-activating gene-3Early phase clinical trialsPrimary treatment failureAggressive skin cancerNew therapeutic agentsICI therapyCheckpoint inhibitorsNovel immunotherapiesMelanoma patientsTreatment failureMetastatic melanomaPredictive biomarkersLong-term benefitsClinical trialsClinical careNew therapiesTherapeutic strategiesAlternative treatmentSkin cancerTherapy outcomeTherapeutic agentsNovel targetNovel therapeuticsPatientsMutation-specific costs of advanced non-small cell lung cancer treatment.
Tan J, Yang S, Dinan M, Chiang A, Gross C, Wang S. Mutation-specific costs of advanced non-small cell lung cancer treatment. JCO Oncology Practice 2023, 19: 14-14. DOI: 10.1200/op.2023.19.11_suppl.14.Peer-Reviewed Original ResearchAdvanced non-small cell lung cancerNon-small cell lung cancerMean medication costsActionable gene alterationsMedication costsFirst-year costsReference groupAdvanced non-small cell lung cancer (NSCLC) treatmentNon-small cell lung cancer (NSCLC) treatmentCell lung cancer treatmentGene alterationsBiomarker resultsFlatiron Health databasePD-L1 resultsTherapy prolongs survivalRetrospective cohort studyCell lung cancerBiomarker test resultsLung cancer treatmentCost-effectiveness analysisCohort studyNovel immunotherapiesOverall cohortProlong survivalTreatment optionsNovel Immune Therapies for Renal Cell Carcinoma Looking Beyond the Programmed Cell Death Protein 1 and Cytotoxic T-Lymphocyte-Associated Protein 4 Axes
Saad E, Saliby R, Labaki C, Xu W, Viswanathan S, Braun D, Bakouny Z. Novel Immune Therapies for Renal Cell Carcinoma Looking Beyond the Programmed Cell Death Protein 1 and Cytotoxic T-Lymphocyte-Associated Protein 4 Axes. Hematology/Oncology Clinics Of North America 2023, 37: 1027-1040. PMID: 37391289, DOI: 10.1016/j.hoc.2023.05.023.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsRenal cell carcinomaCell carcinomaMetastatic renal cell carcinomaCell death protein 1Programmed Cell Death Protein 1Novel immune targetsDeath protein 1Novel immune therapiesNovel immunotherapiesImmune therapyClinical evidenceImmune targetsImmune systemInhibitory stimuliTumoral cellsProtein 1ImmunotherapyPatientsCarcinomaImmunosuppressionTherapySTIMULUS-MDS2 design and rationale: a phase III trial with the anti-TIM-3 sabatolimab (MBG453) + azacitidine in higher risk MDS and CMML-2
Zeidan A, Giagounidis A, Sekeres M, Xiao Z, Sanz G, Van Hoef M, Ma F, Hertle S, Santini V. STIMULUS-MDS2 design and rationale: a phase III trial with the anti-TIM-3 sabatolimab (MBG453) + azacitidine in higher risk MDS and CMML-2. Future Oncology 2023, 19: 631-642. PMID: 37083373, DOI: 10.2217/fon-2022-1237.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsHigh-risk myelodysplastic syndromeChronic myelomonocytic leukemiaMyelodysplastic syndromeCMML-2Tim-3Hematopoietic stem cell transplantationT-cell immunoglobulin domainMucin domain 3Risk myelodysplastic syndromesPhase III trialsStem cell transplantationLeukemic stem cellsFavorable tolerabilityIII trialsNovel immunotherapiesPoor outcomeCell transplantationLeukemic blastsClinical trialsNovel therapiesMyelomonocytic leukemiaDurable benefitImmune systemMyeloid malignanciesMeaningful improvements
2022
A comprehensive review and characterization of nasopharyngeal carcinoma clinical trials
Xu K, De Ravin E, Suresh N, Brody R, Rajasekaran K. A comprehensive review and characterization of nasopharyngeal carcinoma clinical trials. World Journal Of Otorhinolaryngology - Head And Neck Surgery 2022, 9: 174-182. PMID: 37383331, PMCID: PMC10296046, DOI: 10.1002/wjo2.80.Peer-Reviewed Original ResearchPrimary nasopharyngeal carcinomaNasopharyngeal carcinomaClinical trialsSide effectsPD-1 monoclonal antibodyOptimal therapeutic regimensManagement of recurrentPremature study terminationRecent clinical trialsPhase IV trialRetrospective database studyStandard of careNumerous side effectsPercent of trialsNPC trialsMetastatic diseaseNovel immunotherapiesPatient accrualRelapse rateRecurrent cancerRetrospective reviewStudy terminationFuture trialsTherapeutic regimensClinical effectivenessCurrent Therapy for Metastatic Head and Neck Cancer: Evidence, Opportunities, and Challenges.
Wise-Draper TM, Bahig H, Tonneau M, Karivedu V, Burtness B. Current Therapy for Metastatic Head and Neck Cancer: Evidence, Opportunities, and Challenges. American Society Of Clinical Oncology Educational Book 2022, 42: 1-14. PMID: 35486888, DOI: 10.1200/edbk_350442.Peer-Reviewed Original ResearchConceptsNeck squamous cell carcinomaSquamous cell carcinomaMetastatic headCell carcinomaSystemic therapyFirst-line systemic therapyFirst-line immunotherapyInclusion of chemotherapyImmune checkpoint blockadeNew systemic therapiesNumber of patientsAggressive local managementCombination immunotherapyLocoregional therapyOligometastatic diseaseCheckpoint blockadeNovel immunotherapiesPD-L1Lung metastasesRetrospective studyBiomarker subgroupsCurrent therapiesNeck cancerAblative approachesAntiangiogenic agents
2020
Albumin fusion with granulocyte-macrophage colony-stimulating factor acts as an immunotherapy against chronic tuberculosis
Chuang YM, He L, Pinn ML, Tsai YC, Cheng MA, Farmer E, Karakousis PC, Hung CF. Albumin fusion with granulocyte-macrophage colony-stimulating factor acts as an immunotherapy against chronic tuberculosis. Cellular & Molecular Immunology 2020, 18: 2393-2401. PMID: 32382128, PMCID: PMC8484439, DOI: 10.1038/s41423-020-0439-2.Peer-Reviewed Original ResearchConceptsTuberculosis infectionChronic tuberculosis infectionPotent immune responsesGM-CSFLymph nodesDendritic cellsImmune responseChronic Mycobacterium tuberculosis infectionHigher IL-1β levelsAlbumin fusionLung bacillary burdenTB treatment regimensDendritic cell populationsDrug-resistant TBIL-1β levelsGM-CSF administrationMycobacterium tuberculosis infectionNaive T cellsIL-1β releaseBacillary burdenChronic tuberculosisNovel immunotherapiesTreatment regimensVaccination platformSubcutaneous administrationUse of CART cells to selectively target autoantigen-specific T cells for the treatment of autoimmune diabetes
Yu H, Bettini M, Ellis G, Riley J, Collins J, Preston-Hurlburt P, Korah M, Mallone R, Deng S, Wang X, Fremont D, Spiegel D, Cresswell P, Herold K. Use of CART cells to selectively target autoantigen-specific T cells for the treatment of autoimmune diabetes. The Journal Of Immunology 2020, 204: 238.8-238.8. DOI: 10.4049/jimmunol.204.supp.238.8.Peer-Reviewed Original ResearchCART cellsT cellsAutoimmune diabetesCAR constructsHuman antigen-specific CD8Autoantigen-specific T cellsAntigen-specific CD8Pathogenic T cellsPrevious clinical trialsΒ-cell damageChimeric antigen receptorNon-specific actionT cell linesHuman T cellsDominant cell typeHuman insulitisPathogenic subpopulationsNovel immunotherapiesPrimary human T cellsClinical trialsPrimary mediatorPeptide epitopesAntigen receptorMicroglobulin complexCAR signaling18 Adverse kidney effects of immunotherapies
SALY D, PERAZELLA M. 18 Adverse kidney effects of immunotherapies. 2020, 166-182.e3. DOI: 10.1016/b978-0-323-54945-5.00027-8.Peer-Reviewed Original ResearchKidney diseaseDrug-induced kidney diseaseHigh-dose interleukin-2B-cell acute lymphoblastic leukemiaChimeric antigen receptor T cellsAntigen receptor T cellsAdverse kidney effectsImmune checkpoint inhibitorsChronic kidney diseaseChronic kidney injuryNumber of medicationsReceptor T cellsAcute lymphoblastic leukemiaConventional chemotherapeutic drugsAcid-base disturbancesOlder immunotherapiesCheckpoint inhibitorsKidney injuryNovel immunotherapiesNew immunotherapiesCancer patientsKidney effectsKidney lesionsLymphoblastic leukemiaImmune cells
2018
Cancer drugs and the glomerulus
Shah H, Uppal N, Perazella M. Cancer drugs and the glomerulus. Journal Of Onco-Nephrology 2018, 2: 78-91. DOI: 10.1177/2399369318815418.Peer-Reviewed Original ResearchGlomerular lesionsCancer drugsAnti-vascular endothelial growth factor inhibitorsPoor renal outcomeAcute interstitial nephritisAcute kidney injuryAcute tubular necrosisGrowth factor inhibitorsMinimal change diseaseFocal segmental glomerulosclerosisTyrosine kinase inhibitorsNovel cancer drugsRenal outcomesKidney injuryThrombotic microangiopathyNovel immunotherapiesTubular injuryTubular necrosisInterstitial nephritisGlomerular toxicityChange diseaseFactor inhibitorsSegmental glomerulosclerosisGlomerular diseasePodocyte injury
2017
Update on the Renal Effects of Anticancer Agents
Perazella M. Update on the Renal Effects of Anticancer Agents. Journal Of Onco-Nephrology 2017, 1: 170-178. DOI: 10.5301/jo-n.5000026.Peer-Reviewed Original ResearchAnticancer drug nephrotoxicityChronic kidney injuryKidney injuryDrug nephrotoxicityAcute interstitial nephritisAcute kidney injuryAcute tubular injuryNumber of drugsNumber of lesionsAcid-base disturbancesNephrology updateRenal effectsNovel immunotherapiesTubular injuryInterstitial nephritisGlomerular injuryKidney diseaseCancer patientsConventional chemotherapyRenal metabolismSystemic toxicityInjuryNephrotoxicityChemotherapeutic drugsPatients
2012
Poxviral vectors for cancer immunotherapy
Kim JW, Gulley JL. Poxviral vectors for cancer immunotherapy. Expert Opinion On Biological Therapy 2012, 12: 463-478. PMID: 22413824, PMCID: PMC3482162, DOI: 10.1517/14712598.2012.668516.Peer-Reviewed Original ResearchConceptsAppropriate patient selectionClinical trial designPatient selectionTrial designMetastatic castration-resistant prostate cancerPlacebo-controlled clinical trialCastration-resistant prostate cancerNovel immunologic approachesPhase III randomizedScience of immunotherapyImmune-based therapiesMultiple costimulatory moleculesTumor-associated antigensEarly clinical studiesAppropriate end pointsPoxviral vaccinesPSA-TRICOMHormonal therapyNovel immunotherapiesPoxviral vectorsCancer vaccinesCostimulatory moleculesCancer immunotherapyTreatment modalitiesImmunologic approachesThe Role of Gr1+ Cells after Anti-CD20 Treatment in Type 1 Diabetes in Nonobese Diabetic Mice
Hu C, Du W, Zhang X, Wong FS, Wen L. The Role of Gr1+ Cells after Anti-CD20 Treatment in Type 1 Diabetes in Nonobese Diabetic Mice. The Journal Of Immunology 2012, 188: 294-301. PMID: 22140261, PMCID: PMC4361178, DOI: 10.4049/jimmunol.1101590.Peer-Reviewed Original ResearchConceptsType 1 diabetesT cell functionNOD miceCD8 T cell functionRegulatory T cell differentiationAnti-CD20 treatmentPancreatic islet autoimmunityB-cell depletionCell contact-dependent mannerNonobese diabetic (NOD) miceCell functionT cell differentiationContact-dependent mannerDiabetogenic CD4Islet autoimmunityNovel immunotherapiesIL-10Immune toleranceDiabetic miceAutoimmune diseasesCell depletionImmunoregulatory functionsDiabetesMiceDependent manner
2009
Tremelimumab in combination with exemestane as novel immunotherapy for patients with advanced breast cancer
Vonderheide R, LoRusso P, Khalil M, Heath E, Khaira D, Soulieres D, Dorazio P, Mariani G, Usari T, Domchek S. Tremelimumab in combination with exemestane as novel immunotherapy for patients with advanced breast cancer. Journal Of Clinical Oncology 2009, 27: 3034-3034. DOI: 10.1200/jco.2009.27.15_suppl.3034.Peer-Reviewed Original ResearchBreast cancerHormone receptor breast cancerAnti-CTLA4 monoclonal antibodySingle-agent doseUnknown receptor statusCycles of therapyPhase II doseSingle-agent antitumor activityAdvanced breast cancerDose-escalation trialSerum transaminase elevationTumor response evaluationCycle 1Assessment of safetyStable diseaseAdvanced diseasePrimary endpointSecondary endpointsTransaminase elevationAutoimmune thyroiditisHormone replacementNovel immunotherapiesObjective responsePharmacokinetic interactionsReceptor status
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply